The primary objective of the ALiKE Study, conducted by the Vienna Lung Transplant Group, is to improve the outcomes of lung transplant recipients by minimizing the nephrotoxic effects traditionally associated with standard immunosuppressive therapies. This study aims to:
- Develop and evaluate a novel immunosuppression protocol that combines Alemtuzumab induction therapy with a reduced-dose maintenance regimen of Tacrolimus and Everolimus.
- Measure and compare the kidney function, specifically the estimated Glomerular Filtration Rate (eGFR), between the new low-dose protocol and the conventional high-dose immunosuppression treatments.
- Assess the overall immune tolerance of lung transplant recipients towards the transplanted organ under the new treatment regimen.
By achieving these objectives, the ALiKE Study seeks to extend the longevity and enhance the quality of life of lung transplant patients, reducing the long-term adverse effects on the kidneys and other organs.